Table 7 The medians and Weibull parameter of each drug
Classification (ATC code) | Administration route | Case | Median (day) | Scale parameter | Shape parameter |
|---|---|---|---|---|---|
(po: per os; iv: intravenous injection) | (n) | (25–75%) | α (95% CIa) | β (95% CIa) | |
Total | po | 756 | 5.0 (2.0–11.0) | 10.60 (9.68–11.59) | 0.87 (0.82–0.92) |
iv | 1800 | 5.0 (2.0–9.0) | 8.28 (7.88–8.71) | 1.03 (0.99–1.06) | |
Antibacterials | |||||
Combinations of penicillins, incl. Beta-lactamase inhibitors (J01CR) | po | 9 | 3.0 (2.5–11.5) | 8.00 (1.94–30.36) | 0.65 (0.34–1.06) |
iv | 180 | 4.0 (2.0–8.0) | 7.43 (6.34–8.69) | 1.04 (0.93–1.15) | |
Second-generation cephalosporins (J01DC) | po | 8 | 4.5 (1.5–9.0) | 6.95 (3.85–12.12) | 1.79 (0.83–3.20) |
iv | 56 | 3.0 (1.0–5.8) | 5.16 (3.86–6.82) | 1.06 (0.85–1.30) | |
Third-generation cephalosporins (J01DD) | po | 93 | 3.0 (1.0–7.0) | 7.06 (5.47–9.06) | 0.90 (0.77–1.05) |
iv | 138 | 4.0 (2.0–7.0) | 7.23 (6.01–8.66) | 1.02 (0.89–1.15) | |
Fourth-generation cephalosporins (J01DE) | po | 1 | – | – | – |
iv | 83 | 5.0 (2.0–11.0) | 8.24 (6.73–10.02) | 1.19 (0.999–1.40) | |
Carbapenems (J01DH) | po | 0 | – | – | – |
iv | 190 | 5.0 (2.0–9.0) | 8.63 (7.37–10.08) | 1.03 (0.92–1.14) | |
Combinations of sulfonamides and trimethoprim, incl. Derivatives (J01EE) | po | 112 | 8.5 (4.0–21.0) | 17.57 (13.98–21.94) | 0.89 (0.77–1.01) |
iv | 14 | 3.0 (1.8–4.0) | 3.65 (2.54–5.15) | 1.75 (1.12–2.48) | |
Other aminoglycosides (J01GB) | po | 3 | – | – | – |
iv | 143 | 7.0 (3.0–11.0) | 9.64 (8.35–11.09) | 1.27 (1.12–1.43) | |
Fluoroquinolones (J01MA) | po | 232 | 4.0 (2.0–8.0) | 7.62 (6.52–8.89) | 0.92 (0.83–1.01) |
iv | 95 | 4.0 (2.0–7.0) | 7.00 (5.72–8.53) | 1.14 (0.97–1.33) | |
Glycopeptide antibacterials (J01XA) | po | 10 | 7.0 (2.0–10.3) | 13.15 (4.90–33.47) | 0.79 (0.47–1.18) |
iv | 353 | 5.0 (2.0–10.0) | 8.69 (7.82–9.63) | 1.10 (1.01–1.18) | |
Polymyxins (J01XB) | po | 0 | – | – | – |
iv | 83 | 3.0 (1.0–6.0) | 6.25 (5.07–7.64) | 1.26 (1.05–1.49) | |
Other antibacterials (J01XX) | po | 9 | 10.0 (5.5–12.0) | 10.06 (6.65–14.84) | 2.07 (1.13–3.27) |
iv | 39 | 3.0 (1.0–7.0) | 7.75 (4.92–11.98) | 0.86 (0.66–1.09) | |
Antimycotics | |||||
Antibiotics (J02AA) | po | 3 | – | – | – |
iv | 154 | 5.0 (2.0–9.3) | 9.00 (7.45–10.82) | 0.94 (0.83–1.05) | |
Triazole derivatives (J02AC) | po | 88 | 9.5 (3.0–23.0) | 19.11 (14.82–24.44) | 0.94 (0.79–1.11) |
iv | 59 | 5.0 (2.0–18.0) | 13.06 (9.27–18.17) | 0.83 (0.68–1.01) | |
Other antimycotics for systemic use (J02AX) | po | 2 | – | – | – |
iv | 82 | 5.0 (3.0–11.0) | 10.84 (8.42–13.86) | 0.96 (0.81–1.12) | |